source
- Genentech pays Alector $100M for preclinical Parkinson’s prospectGenentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver of neurodegeneration in Parkinson’s disease.
- FDA warns Evolus over misleading Instagram claims about JeuveauThe FDA's Office of Prescription Drug Promotion sent an untitled warning letter to Evolus, the maker of the injectable cosmetic product Jeuveau. The letter says the company exaggerated the drug’s…